Maxim Group analyst Jason McCarthy assigned a Buy rating to TFF Pharmaceuticals (TFFP) yesterday and set a price target of $18.00. The company’s shares closed last Friday at $13.34.
According to TipRanks.com, McCarthy is a top 100 analyst with an average return of 45.0% and a 52.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
TFF Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $29.50, representing an 118.5% upside. In a report issued on February 19, B.Riley Financial also reiterated a Buy rating on the stock with a $36.00 price target.
See today’s analyst top recommended stocks >>
Based on TFF Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.06 million. In comparison, last year the company had a GAAP net loss of $2.84 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TFFP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TFF Pharmaceuticals, Inc. operates as an early-stage biopharmaceutical company. It develops and commercializes drug products based on its Thin film Freezing (TFF) technology platform. The firm also engages in research, development & drug formulation and initial testing of drug products. The company was founded in 2005 and is headquartered in Toronto, Canada.
